TrialNature communications2026

Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.

Peter Nordbeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.